Physician profile
Robert P Marshburn
NPI 1629184395
$1,619.48
in general payments reported to CMS, 2019-2025
23 companies · $45.74 in 2025
The $45.74 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $350 · 2021: $404 · 2022: $70.07 · 2023: $125 · 2024: $278 · 2025: $45.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $448.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $351.77 | 2019-2021 | |
| Abbott Laboratories | $163.03 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $156.08 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $130.80 | 2019-2024 | Repatha |
| Mylan Specialty L.P. | $106.52 | 2019-2024 | Yupelri |
| Lilly USA, LLC | $86.93 | 2020-2024 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.62 | 2019-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $81.90 | 2019-2022 | |
| Pfizer INC. | $77.48 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $72.93 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $47.24 | 2023-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $45.66 | 2020-2024 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.51 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $26.87 | 2025 | Voquezna |
| Horizon Therapeutics Plc | $22.63 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $22.15 | 2022 | |
| Exact Sciences Corporation | $19.92 | 2024 | Cologuard Collection Kit |
| Abiomed | $19.20 | 2024 | Impella |
| Esperion Therapeutics, INC. | $17.59 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.72 | 2021 | |
| Novo Nordisk INC | $15.31 | 2019 | |
| Merck Sharp & Dohme LLC | $13.65 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.97 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Marshburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.